secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001193125-23-052289
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics appoints Adam Crystal as President, R&D; base salary $550k, equity grants
--------------------------------------------------------------------------------

- Adam Crystal, M.D., Ph.D., appointed President, Research & Development, effective Feb 27, 2023.
- Annual base salary of $550,000; one-time sign-on bonus of $275,000 (clawback if leaves before Feb 27, 2024).
- Equity grants: stock options for 487,500 shares and RSUs for 81,250 shares, with time-based vesting.
- Target annual cash incentive of 45% of base salary; severance includes 12 months salary and COBRA coverage.
- Crystal previously CMO at C4 Therapeutics and clinical program leader at Novartis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312523052289/0001193125-23-052289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312523052289/d297639d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-052289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer